Abstract
Everolimus-eluting stents have become the most commonly used drug-eluting stents (DES), in part because of data from clinical trials showing significantly reduced rates of revasculization, myocardial infarction (MI), and stent thrombosis with the PROMUS or XIENCE V everolimus-eluting, cobalt-chromium stent compared with early generation paclitaxel-eluting stents.
Original language | English |
---|---|
Pages (from-to) | 1117-1123 |
Number of pages | 7 |
Journal | The American Journal of Cardiology |
Volume | 113 |
Issue number | 7 |
DOIs | |
Publication status | Published - 2014 |
Externally published | Yes |